Up-front melphalan in Ewing's family tumors with bone/bone marrow metastases at onset (very-high risk EFTs). A report from ISG/AIEOP 'Very High Risk EFTs Cooperative Study'

Autor:	Angela Tamburini, Sandra Aliberti, Franca Fagioli, G. Hanau, Silvia Ferrari, A. Prete, P. Picci, Roberto Luksch, E. Grignani, Michela Casanova
Rok vydání:	2004
Předmět:	EFTS Oncology Melphalan Cancer Research medicine.medical_specialty Chemotherapy business.industry medicine.medical_treatment Neutropenia medicine.disease Surgery Radiation therapy medicine.anatomical_structure Internal medicine Toxicity medicine Bone marrow business Very high risk medicine.drug
Zdroj:	Journal of Clinical Oncology. 22:9037-9037
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2004.22.90140.9037
Popis:	9037 Background:Patients with very-high risk EFTs have a poor prognosis. Melphalan (L-PAM) has been widely used in myeloablative regimens in EFTs, without a prior demonstration of its effectiveness in this disease. Methods: From March 2001, a study was opened for very-high risk EFTs with the main aim to investigate the activity and toxicity of up-front L-PAM at non myeloablative doses. Treatment consisted of initial window-therapy with L-PAM (50 mg/m2 every 21 days × 2 courses) followed by 8 intensive chemotherapy courses, and consolidation with megatherapy+autologous PBSC rescue. PBSC collection was scheduled in responders after the 4th/6th chemotherapy course. Surgery and radiotherapy were employed on individual basis Results: As of September 2003, 17 consecutive patients (median age 16yrs, range 9–34) were enrolled. All patients were evaluable for toxicity and up-front L-PAM activity. No severe toxicities were reported, but for grade 3–4 hemopoietic toxicity. After L-PAM courses, grade 4 neutropenia, t...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::8e785e70b770caaada0abf9e82591d9e https://doi.org/10.1200/jco.2004.22.90140.9037 Zobrazit plný text záznamu